Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

Launched by M.D. ANDERSON CANCER CENTER · Mar 10, 2025

Keywords

ClinConnect Summary

The MUCOR-ADVANCE clinical trial is studying serious fungal infections, specifically mucormycosis, in patients who have cancer. The goal is to collect important information and samples from participants to better understand how these infections affect people with cancer and to find better ways to treat them. This research is crucial because patients with weakened immune systems, like those undergoing cancer treatment, are at higher risk for these infections.

To be eligible for this trial, participants need to be between 18 and 100 years old and must have cancer along with either invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infections. They also need to be open to undergoing routine medical tests, such as blood draws or biopsies, as part of their regular healthcare. The trial is not currently recruiting participants, but when it begins, those who join can expect to contribute to important research that may help improve treatment options for themselves and others facing similar health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection.
• • Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care.
• Exclusion Criteria:
• • • Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.